Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 2 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PARACELSUS PHARMA PROJECTS from Aalter, company number BE0475409569, closed financial year 2025 with a result of € -10,092 after tax. For that financial year PARACELSUS PHARMA PROJECTS recorded a gross margin of € 9,489 and equity of € 107,010. Compared with financial year 2024, the result moved from € -2,505 to € -10,092. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ 107,010
▼ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -10,092
▼ 303 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1,284
▼ 89% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 88,410.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,832
▲ 212% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 174
▼ 54% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 16,910 | € 12,576 | € 16,954 | € 9,489 | ▼ 44% |
| Profit after taxes | € -5,286 | € -6,852 | € -2,505 | € -10,092 | ▼ € 7,587 |
| Equity | € 126,459 | € 119,607 | € 117,102 | € 107,010 | ▼ 9% |
| Total debts | € 125,900 | € 117,937 | € 110,433 | € 90,170 | ▼ 18% |
| Cash | € 3,756 | € 5,324 | € 12,006 | € 1,284 | ▼ 89% |
| Land & buildings | € 247,312 | € 229,819 | € 212,327 | € 194,835 | ▼ 8% |
| Retained profit | € 107,859 | € 101,007 | € 98,502 | € 88,410 | ▼ 10% |
| Balance sheet total | € 252,359 | € 237,544 | € 227,534 | € 197,179 | ▼ 13% |
Key figures of PARACELSUS PHARMA PROJECTS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PARACELSUS PHARMA PROJECTS?
What happened at PARACELSUS PHARMA PROJECTS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 10,092. Source: NBB ↗
- Annemieke Vergauwe became a director. NBB
- New establishment in Aalter. KBO
- Start of the company according to the CBE. KBO
In short
From € 5,286 loss in 2022 to € 10,092 loss in 2025.
Paid € 613 in corporate taxes since 2022.
Management
Behind PARACELSUS PHARMA PROJECTS is Annemieke Vergauwe.
Directors
According to the 2025 annual accounts
Annemieke Vergauwe
Director
since 2009
Establishments
Establishment units
Physical locations of this company
Aalterveld 26
9880 Aalter
Pontweg 30
9880 Aalter
Active since 21 September 2001
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0475.409.569
- VAT number
- BE 0475.409.569
- Registered office
- Aalterveld 26, 9880 Aalter
- Names & denominations
- PARACELSUS PHARMA PROJECTS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 1 August 2001
- Peppol
- Active · Active since 12 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers